- Home
- ALLO vs BGH Comparison
ALLO vs BGH Comparison
Compare ALLO & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- BGH
- Stock Information
- Founded
- ALLO 2017
- BGH 2012
- Country
- ALLO United States
- BGH United States
- Employees
- ALLO N/A
- BGH N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- BGH Investment Managers
- Sector
- ALLO Health Care
- BGH Finance
- Exchange
- ALLO Nasdaq
- BGH Nasdaq
- Market Cap
- ALLO 338.9M
- BGH 318.8M
- IPO Year
- ALLO 2018
- BGH N/A
- Fundamental
- Price
- ALLO $1.44
- BGH $15.15
- Analyst Decision
- ALLO Strong Buy
- BGH
- Analyst Count
- ALLO 10
- BGH 0
- Target Price
- ALLO $9.66
- BGH N/A
- AVG Volume (30 Days)
- ALLO 3.3M
- BGH 61.5K
- Earning Date
- ALLO 05-12-2025
- BGH 01-01-0001
- Dividend Yield
- ALLO N/A
- BGH 10.06%
- EPS Growth
- ALLO N/A
- BGH N/A
- EPS
- ALLO N/A
- BGH N/A
- Revenue
- ALLO $22,000.00
- BGH N/A
- Revenue This Year
- ALLO N/A
- BGH N/A
- Revenue Next Year
- ALLO $8.30
- BGH N/A
- P/E Ratio
- ALLO N/A
- BGH N/A
- Revenue Growth
- ALLO N/A
- BGH N/A
- 52 Week Low
- ALLO $1.30
- BGH $11.92
- 52 Week High
- ALLO $4.30
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- ALLO 36.16
- BGH 36.93
- Support Level
- ALLO $1.49
- BGH $14.97
- Resistance Level
- ALLO $1.69
- BGH $15.35
- Average True Range (ATR)
- ALLO 0.14
- BGH 0.14
- MACD
- ALLO -0.03
- BGH 0.00
- Stochastic Oscillator
- ALLO 17.50
- BGH 45.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.